What AI Consulting and Compliance Means for a Healthtech Founder
AI consulting and compliance for a healthtech founder covers the intersection of three domains that most consultants address separately: AI engineering, healthcare regulation, and NHS procurement. A technology consultant who does not understand DTAC will give you technically sound advice that fails at NHS adoption. A regulatory consultant who does not understand AI architecture will give you compliance guidance that is theoretically correct but technically impractical. A procurement consultant who does not understand AI will miss the specific requirements that clinical AI systems face in NHS evaluation. SpeedMVPs addresses all three in a single engagement. The consulting output is a set of written recommendations and technical specifications that tell you: whether your intended AI approach is technically feasible given the clinical data you have access to, which MHRA regulatory pathway applies to your product and what it requires, what DTAC evidence you will need and whether your current design generates that evidence, what GDPR Article 9 legal basis applies to your processing of patient data and what technical controls it requires, whether your intended AI architecture is compatible with NHS Digital data security requirements, and how the EU AI Act risk classification affects your product if you intend to sell into EU markets. These are not generic recommendations. They are specific to your product, your intended market, and the data you have access to. The consulting engagement produces documentation you can use with NHS clinical champions, CCGs, ICBs, and NHS trust procurement teams as evidence that your product has been designed with clinical governance and regulatory compliance in mind.
Our Consulting Process for Healthtech AI Compliance
The consulting process begins with a structured discovery session covering your product's intended purpose, the clinical context of use, the intended user, the data the AI will process and where it will come from, the NHS organisations you are targeting, and the timeline you are working to. This session is a prerequisite because the regulatory pathway, the DTAC domains that apply, and the GDPR legal basis all depend on these specifics. A product that analyses GP records for population health management is in a completely different regulatory position from a product that helps patients manage their own chronic conditions at home. After the discovery session, we produce a regulatory mapping document that identifies every framework that applies to your product and the specific requirements within each that you need to address before NHS deployment. This document is structured to be actionable: for each requirement, it describes what you need to demonstrate, what evidence you need to produce, and whether your current design already produces that evidence or whether a change is needed. The technical review covers your proposed AI architecture, model selection, data pipeline design, and explainability approach. We identify the architecture decisions that are incompatible with your regulatory requirements and propose alternatives. We also identify the technical decisions that will make your DTAC evidence generation easier, such as logging approaches that produce the audit trail DTAC clinical safety assessment requires, and authentication patterns that satisfy DTAC technical security requirements. The GDPR review identifies the legal basis for each category of patient data processing, the technical controls required by the legal basis, and the additional safeguards required for special category health data under Article 9.
Deliverables from a Healthtech AI Consulting Engagement
The consulting engagement produces a set of written outputs designed to be genuinely useful rather than decorative. The regulatory pathway report describes which regulations apply to your product, what they require, and the evidence needed to satisfy each requirement. For products that are likely medical devices, this includes the MHRA risk classification, the conformity assessment route, and the technical file requirements. For products facing DTAC assessment, this includes a DTAC readiness matrix showing which evidence items you have, which you need to produce, and which require architectural changes to become achievable. The technical architecture review report describes the proposed AI architecture, the regulatory constraints it needs to satisfy, the design changes required to satisfy them, and the rationale for each recommendation. This document is written at a level of technical detail that your developers can implement from. The GDPR compliance framework document covers the legal basis for each processing activity, the data subject rights that apply to health data subjects, the retention periods for different categories of patient data, the international transfer controls if your AI uses a non-UK model provider, and the data protection impact assessment structure. The NHS digital engagement strategy document describes how to approach NHS trust digital teams, what evidence they will ask for, how to prepare for DTAC assessment, and what the DSP Toolkit assessment involves for your product category. The investment readiness brief is a short document summarising the regulatory position for investor conversations, describing the pathway to NHS adoption and the key milestones along it.
MHRA, DTAC, and NHS Digital: What Each Framework Requires
The three principal regulatory frameworks for clinical AI in the NHS apply in sequence and in some cases simultaneously. Understanding what each requires and when each becomes relevant is one of the most practically useful outputs of a consulting engagement. MHRA medical device regulation becomes relevant immediately if your product meets the definition of a medical device. That definition is broader than most founders initially assume: software that uses patient data to make or inform a diagnosis, a prognosis, or a treatment recommendation is likely to be a medical device. The MHRA's guidance document DENI (Determining if a device or diagnostic meets the definition of a medical device) is the primary reference, and we apply its decision framework to your specific product during the regulatory mapping exercise. DTAC assessment is required for NHS organisations considering adopting your product. It covers five domains: clinical safety under DCB0129, data protection, technical security, interoperability, and usability. The clinical safety domain requires a clinical safety case and hazard log prepared by a qualified Clinical Safety Officer. If you do not have a CSO, we can advise on engaging one. The other four domains require evidence that your product meets their specific standards, and we help you understand what evidence is needed and whether your current design produces it. NHS Digital Data Security and Protection Toolkit assessment applies if your product will access NHS patient data directly or be deployed by an NHS organisation. The DSP Toolkit has specific technical assertions that your product needs to satisfy, including encryption standards, access management, and incident response. We map the relevant assertions to your architecture and identify the gaps.
EU AI Act Implications for Clinical AI Products
The EU AI Act, which entered into force in August 2024 with staggered application dates, creates significant new obligations for AI systems used in healthcare. Clinical AI systems that assist in clinical decision-making are likely to be classified as high-risk AI systems under Annex III, Article 6(2), which means they face the most demanding requirements under the Act. High-risk AI systems require: a risk management system covering the AI system's lifecycle, a quality management system, comprehensive technical documentation describing the system's purpose, architecture, data, and validation, data governance procedures covering the training, validation, and testing data, transparency and provision of information to users, human oversight measures, accuracy and robustness standards, and registration in the EU AI Act database before being placed on the EU market. For healthtech founders with EU market ambitions, these requirements have implications for the architecture decisions made at MVP stage. Building an audit trail that satisfies Article 12's logging requirements for high-risk AI systems is significantly easier when designed in from the start than when retrofitted onto an existing system. Conformity assessment for high-risk AI systems in healthcare may require involvement of a notified body, particularly where the AI system is also a medical device. We assess the EU AI Act classification for your product during the consulting engagement and produce the documentation outline required for high-risk AI system compliance.
Why Healthtech Founders Choose SpeedMVPs for AI Compliance Consulting
The founders who benefit most from a SpeedMVPs consulting engagement are those who have a clear clinical problem they want to solve with AI but are uncertain about whether the regulatory pathway is navigable and what it will cost to navigate. The consulting engagement gives you the information to make that decision with confidence. If the regulatory pathway is straightforward and the technical approach is sound, the consulting engagement produces the architecture specification and regulatory evidence framework for a subsequent build engagement. If the regulatory pathway is more demanding than initially anticipated, the consulting engagement gives you the honest assessment you need to decide whether the market opportunity justifies the additional investment and timeline. We do not tell founders what they want to hear in order to win a subsequent build engagement. We give them the honest regulatory and technical assessment, even when that means identifying significant obstacles. The healthtech founders who appreciate this approach are the ones who go on to build products that actually get deployed by NHS trusts, rather than products that fail at DTAC assessment after 18 months of development. Our consulting engagements also produce documents that are useful beyond the immediate build decision. The regulatory pathway report is a credible evidence piece for investor conversations about the regulatory risk profile of the business. The DTAC readiness matrix is a practical working document for the NHS trust engagement process. The GDPR compliance framework is a real foundation for ICO registration and NHS data sharing agreement negotiations. Get a free consultation at speedmvps.co.uk